Crinetics Pharmaceuticals (CRNX) Share-based Compensation: 2017-2025
Historic Share-based Compensation for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Sep 2025 value amounting to $22.7 million.
- Crinetics Pharmaceuticals' Share-based Compensation rose 25.10% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.1 million, marking a year-over-year increase of 41.81%. This contributed to the annual value of $69.4 million for FY2024, which is 69.49% up from last year.
- Crinetics Pharmaceuticals' Share-based Compensation amounted to $22.7 million in Q3 2025, which was down 13.10% from $26.1 million recorded in Q2 2025.
- Over the past 5 years, Crinetics Pharmaceuticals' Share-based Compensation peaked at $26.1 million during Q2 2025, and registered a low of $3.4 million during Q1 2021.
- In the last 3 years, Crinetics Pharmaceuticals' Share-based Compensation had a median value of $18.1 million in 2024 and averaged $16.3 million.
- Data for Crinetics Pharmaceuticals' Share-based Compensation shows a peak YoY skyrocketed of 86.14% (in 2024) over the last 5 years.
- Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' Share-based Compensation stood at $5.2 million in 2021, then spiked by 54.09% to $7.9 million in 2022, then spiked by 46.16% to $11.6 million in 2023, then spiked by 62.22% to $18.8 million in 2024, then increased by 25.10% to $22.7 million in 2025.
- Its Share-based Compensation stands at $22.7 million for Q3 2025, versus $26.1 million for Q2 2025 and $20.5 million for Q1 2025.